SAVA Stock Alert: Former Cassava Science Advisor Charged With Fraud

Shares of Cassava Sciences (NASDAQ:SAVA), which has an Alzheimer's drug candidate called simufilam, fell 35% on June 28 and another 13% over the weekend. This move in SAVA stock comes after a key science advisor was charged with defrauding the National Institutes of Health (NIH). We may be getting our answer. Last year, a CUNY investigation found signs that images in Wang's early papers were manipulated. This included a 2012 paper indicating simufilam "can blunt the pathological effects of beta amyloid, a p ...